Bank of New York Mellon Corp Sells 53,175 Shares of Conatus Pharmaceuticals Inc (CNAT)
Bank of New York Mellon Corp decreased its position in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) by 24.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 165,834 shares of the biotechnology company’s stock after selling 53,175 shares during the quarter. Bank of New York Mellon Corp’s holdings in Conatus Pharmaceuticals were worth $711,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its holdings in Conatus Pharmaceuticals by 253.0% in the first quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 16,476 shares during the period. Wells Fargo & Company MN lifted its holdings in Conatus Pharmaceuticals by 63.4% in the first quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 21,564 shares during the period. LMR Partners LLP bought a new position in Conatus Pharmaceuticals in the second quarter valued at about $311,000. JPMorgan Chase & Co. lifted its holdings in Conatus Pharmaceuticals by 1,205.7% in the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock valued at $435,000 after acquiring an additional 68,390 shares during the period. Finally, BlackRock Inc. lifted its holdings in Conatus Pharmaceuticals by 45.4% in the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock valued at $13,601,000 after acquiring an additional 723,413 shares during the period. 33.50% of the stock is currently owned by institutional investors.
NASDAQ CNAT opened at $4.77 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.35 and a current ratio of 2.35. Conatus Pharmaceuticals Inc has a 52 week low of $3.22 and a 52 week high of $7.95. The stock has a market capitalization of $155.55 million, a PE ratio of -7.87 and a beta of 1.38.
A number of research firms have weighed in on CNAT. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. ValuEngine downgraded Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Finally, Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $11.80.
Conatus Pharmaceuticals Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Article: Put Option
Want to see what other hedge funds are holding CNAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Conatus Pharmaceuticals Inc (NASDAQ:CNAT).
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.